Literature DB >> 12642303

Amiodarone induced optic neuropathy.

P K Nagra1, R Foroozan, P J Savino, I Castillo, R C Sergott.   

Abstract

AIM: To determine the clinical features of amiodarone induced optic neuropathy, which may help distinguish it from non-arteritic anterior ischaemic optic neuropathy.
METHODS: Retrospective observational case series of patients diagnosed with amiodarone induced optic neuropathy at the neuro-ophthalmology service from March 1998 to February 2001. Amiodarone was discontinued after discussion with the patient's cardiologist. Visual acuity, colour vision, automated perimetry, and funduscopy were performed on initial and follow up examinations.
RESULTS: Three patients with amiodarone induced optic neuropathy presented with mildly decreased vision, visual field defects, and bilateral optic disc swelling. Upon discontinuing the medication, visual function and optic disc swelling slowly improved in all three patients.
CONCLUSION: Amiodarone induced optic neuropathy can present with visual dysfunction, and is typically a bilateral process. Upon discontinuation of amiodarone, slow resolution of optic disc swelling occurs and visual function improves in some patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12642303      PMCID: PMC1771608          DOI: 10.1136/bjo.87.4.420

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  13 in total

Review 1.  Ischemic optic neuropathies.

Authors:  A C Arnold
Journal:  Ophthalmol Clin North Am       Date:  2001-03

2.  Guidelines 2000 for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Part 6: advanced cardiovascular life support: section 1: Introduction to ACLS 2000: overview of recommended changes in ACLS from the guidelines 2000 conference. The American Heart Association in collaboration with the International Liaison Committee on Resuscitation.

Authors: 
Journal:  Circulation       Date:  2000-08-22       Impact factor: 29.690

3.  Optic neuropathy following amiodarone therapy.

Authors:  A G Sreih; M H Schoenfeld; M A Marieb
Journal:  Pacing Clin Electrophysiol       Date:  1999-07       Impact factor: 1.976

4.  Serum concentrations of amiodarone during long term therapy. Relation to dose, efficacy and toxicity.

Authors:  M Stäubli; J Bircher; R L Galeazzi; H Remund; H Studer
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

Review 5.  Clinical organ toxicity of antiarrhythmic compounds: ocular and pulmonary manifestations.

Authors:  P T Pollak
Journal:  Am J Cardiol       Date:  1999-11-04       Impact factor: 2.778

6.  [Amiodarone-associated optic neuropathy: an independent syndrome? Three patients with bilateral optic neuropathy].

Authors:  D Leifert; L L Hansen; J Gerling
Journal:  Klin Monbl Augenheilkd       Date:  2000-09       Impact factor: 0.700

7.  Amiodarone-related optic neuropathy.

Authors:  T Eryilmaz; H Atilla; F Batioglu; I Günalp
Journal:  Jpn J Ophthalmol       Date:  2000 Sep-Oct       Impact factor: 2.447

8.  Optic neuropathy and amiodarone therapy.

Authors:  L A Feiner; B R Younge; F J Kazmier; B H Stricker; F T Fraunfelder
Journal:  Mayo Clin Proc       Date:  1987-08       Impact factor: 7.616

9.  Bilateral optic neuropathy associated with amiodarone therapy.

Authors:  S M Nazarian; W M Jay
Journal:  J Clin Neuroophthalmol       Date:  1988-03

10.  Optic nerve ultrastructure following amiodarone therapy.

Authors:  A M Mansour; J E Puklin; R O'Grady
Journal:  J Clin Neuroophthalmol       Date:  1988-12
View more
  11 in total

1.  Behaviour of disc oedema during and after amiodarone optic neuropathy: case report.

Authors:  Med Alejandro Martínez-LóPez-Portillo; Bertha O Martínez-Gamero; Jibran Mohamed-Noriega; Med Humberto Cavazos-Adame; Med Jesús Mohamed-Hamsho
Journal:  J Clin Diagn Res       Date:  2014-04-15

2.  'White elephants' and a distinguished monkey - or the need for a proactive follow-up in amiodarone therapy.

Authors:  Chr van Tellingen
Journal:  Neth Heart J       Date:  2004-10       Impact factor: 2.380

Review 3.  Amiodarone-associated optic neuropathy: a critical review.

Authors:  Rod S Passman; Charles L Bennett; Joseph M Purpura; Rashmi Kapur; Lenworth N Johnson; Dennis W Raisch; Dennis P West; Beatrice J Edwards; Steven M Belknap; Dustin B Liebling; Mathew J Fisher; Athena T Samaras; Lisa-Gaye A Jones; Katrina-Marie E Tulas; June M McKoy
Journal:  Am J Med       Date:  2012-03-03       Impact factor: 4.965

Review 4.  Amiodarone-Associated Optic Neuropathy: Clinical Review.

Authors:  An-Guor Wang; Hui-Chen Cheng
Journal:  Neuroophthalmology       Date:  2016-11-18

5.  Unusual and early hyperglycemia following amiodarone infusion in two infants.

Authors:  S V Yildirim; E Azak; B Varan; K Tokel
Journal:  Pediatr Cardiol       Date:  2005 Sep-Oct       Impact factor: 1.655

6.  Amiodarone-associated Optic Neuropathy-A Clinical Criteria-based Diagnosis?

Authors:  Katrin Fasler; Ghislaine L Traber; Gregor Peter Jaggi; Klara Landau
Journal:  Neuroophthalmology       Date:  2017-08-18

Review 7.  The clinical spectrum of amiodarone-associated optic neuropathy.

Authors:  Lenworth N Johnson; Gregory B Krohel; Eric R Thomas
Journal:  J Natl Med Assoc       Date:  2004-11       Impact factor: 1.798

Review 8.  [Clinical aspects of treatment with amiodarone].

Authors:  W Haverkamp; C Israel; A Parwani
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2017-09

9.  Absence of bilateral vision loss from amiodarone: a randomized trial.

Authors:  Joel S Mindel; Jill Anderson; Anne Hellkamp; George Johnson; Jeanne E Poole; Daniel B Mark; Kerry L Lee; Gust H Bardy
Journal:  Am Heart J       Date:  2007-05       Impact factor: 4.749

10.  Stem Cell Ophthalmology Treatment Study: bone marrow derived stem cells in the treatment of non-arteritic ischemic optic neuropathy (NAION).

Authors:  Jeffrey N Weiss; Steven Levy; Susan C Benes
Journal:  Stem Cell Investig       Date:  2017-11-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.